Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donanemab in Early Symptomatic Alzheimer's Disease
NCT05508789Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2022
- Primary completion
- May 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of donanemab in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Oct 2022; status: active, not recruiting.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05508789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05508789.